|Assessment Process Complete
|For the Treatment of Deep Vein Thrombosis (DVT), and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Cost effective at submitted price
We consider that at the submitted price Rivaroxaban could be considered cost-effective for this indication.